NDC 61755-021

Praluent

Alirocumab

Praluent is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Regeneron Pharmaceuticals, Inc.. The primary component is Alirocumab.

• Product ID: 61755-021_03a8dbf0-1310-4003-982e-9c4d9bed7896
• NDC: 61755-021
• Product Type: Human Prescription Drug
• Proprietary Name: Praluent
• Generic Name: Alirocumab
• Dosage Form: Injection, Solution
• Route of Administration: SUBCUTANEOUS
• Marketing Start Date: 2019-02-15
• Marketing Category: BLA / BLA
• Application Number: BLA125559
• Labeler Name: Regeneron Pharmaceuticals, Inc.
• Substance Name: ALIROCUMAB
• Active Ingredient Strength: 150 mg/mL
• Pharm Classes: PCSK9 Inhibitor [EPC],PCSK9 Inhibitors [MoA],Antibodies, Monoclonal [CS]
• NDC Exclude Flag: N
• Listing Certified Through: 2021-12-31

Packaging

NDC 61755-021-01

1 SYRINGE, GLASS in 1 CARTON (61755-021-01) > 1 mL in 1 SYRINGE, GLASS

• Marketing Start Date: 2020-12-01
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details

NDC Crossover Matching brand name "Praluent" or generic name "Alirocumab"

NDC	Brand Name	Generic Name
0024-5901	Praluent	alirocumab
0024-5902	Praluent	alirocumab
0024-5903	Praluent	alirocumab
0024-5904	Praluent	alirocumab
61755-020	Praluent	alirocumab
72733-5901	Praluent	Praluent
72733-5902	Praluent	Praluent
61755-021	Praluent	Praluent